急性心肌梗塞患者尿激酶治疗前后血浆纤维连结蛋白和VW因子水平的观察

OBSERVATION OF PLASMA FIBRONECTIN AND VON WILLEBRAND FACTOR IN AMI PATIENTS PRE AND POST TREATMENT WITH UROKINASE

应用酶联免疫吸附法及散射速率比浊法观察22例急性心肌梗塞(AMI)患者血浆纤维连接蛋白(Fibronectin,Fn)及VW因子(von Willebrand)的血浆含量变化,其中11例病人进行尿激酶(Uk)治疗前后的动态观察。结果表明:AMI早期,血浆VW因子、Fn含量增加,提示与内皮细胞破坏有关;Uk治疗前后对血浆vW因子含量无影响;应用Uk后24h,Fn水平明显降低,72h Fn水平复升,推测其干预机体纤溶系统的稳定性;Uk治疗前后VW因子与Uk水平无相关。

Plasma fibronectin(Fn)and von Willebrand factor(VWF) levels were determined in 22 acute myocardial infarction (AMI), 11 of them were measured pre-and-post treatment with urokinase (UK.1,000, 000 IU). The results revealed plasma Fn and VWF contents increased in AMI early phase; plasma VWF levels had no change pre-and-post treatment with UK; plasma Fn levels cecreased much in 24 hours with UK treatment; high up again after 72 hours and no difference compared with pre treatment. The results suggested increased release of VWF and Fn levels related to endothelial damage in AMI early phase; change of Fn levels might interfere and improve stabilization of fibrinolytic system UK treatment.